Protocol Biopsies

Utility and Limitations

Yihung Huang, Evan Farkash

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

As both T cell and antibody–mediated rejection can have a subclinical phase, protocol biopsies provide an early opportunity to intervene before the onset of clinical allograft dysfunction. Protocol biopsies are usually done after reperfusion to establish baseline, between 3 and 6 months to identify subclinical rejection, and at 6-12 months to assess chronicity and persistent inflammation that have prognostic implication. Treatment of both subclinical T cell and antibody–mediated rejection prevents progression of rejection and development of interstitial fibrosis/tubular atrophy or transplant glomerulopathy. Although subclinical rejection has become less frequent in low-risk patients on triple immunosuppression containing tacrolimus, protocol biopsies may still be useful in selected population. Protocol biopsies are more likely to benefit patients at higher risk for rejection, including those who are highly sensitized, transplanted across donor-specific antibody barriers, or on calcineurin inhibitor/corticosteroids sparing regimens. Interstitial fibrosis on protocol biopsies, especially in conjunction with persistent inflammation, predicts lower allograft survival.

Original languageEnglish (US)
Pages (from-to)326-331
Number of pages6
JournalAdvances in Chronic Kidney Disease
Volume23
Issue number5
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

Biopsy
Allografts
Fibrosis
Inflammation
T-Lymphocytes
Tacrolimus
Immunosuppression
Reperfusion
Atrophy
Adrenal Cortex Hormones
Tissue Donors
Transplants
Antibodies
Population
Therapeutics

Keywords

  • Allograft survival
  • Protocol biopsies
  • Subclinical rejection

ASJC Scopus subject areas

  • Nephrology

Cite this

Protocol Biopsies : Utility and Limitations. / Huang, Yihung; Farkash, Evan.

In: Advances in Chronic Kidney Disease, Vol. 23, No. 5, 01.09.2016, p. 326-331.

Research output: Contribution to journalReview article

Huang, Yihung ; Farkash, Evan. / Protocol Biopsies : Utility and Limitations. In: Advances in Chronic Kidney Disease. 2016 ; Vol. 23, No. 5. pp. 326-331.
@article{90fc9c615ad54c80a15427de5a4ac25d,
title = "Protocol Biopsies: Utility and Limitations",
abstract = "As both T cell and antibody–mediated rejection can have a subclinical phase, protocol biopsies provide an early opportunity to intervene before the onset of clinical allograft dysfunction. Protocol biopsies are usually done after reperfusion to establish baseline, between 3 and 6 months to identify subclinical rejection, and at 6-12 months to assess chronicity and persistent inflammation that have prognostic implication. Treatment of both subclinical T cell and antibody–mediated rejection prevents progression of rejection and development of interstitial fibrosis/tubular atrophy or transplant glomerulopathy. Although subclinical rejection has become less frequent in low-risk patients on triple immunosuppression containing tacrolimus, protocol biopsies may still be useful in selected population. Protocol biopsies are more likely to benefit patients at higher risk for rejection, including those who are highly sensitized, transplanted across donor-specific antibody barriers, or on calcineurin inhibitor/corticosteroids sparing regimens. Interstitial fibrosis on protocol biopsies, especially in conjunction with persistent inflammation, predicts lower allograft survival.",
keywords = "Allograft survival, Protocol biopsies, Subclinical rejection",
author = "Yihung Huang and Evan Farkash",
year = "2016",
month = "9",
day = "1",
doi = "10.1053/j.ackd.2016.09.002",
language = "English (US)",
volume = "23",
pages = "326--331",
journal = "Advances in Chronic Kidney Disease",
issn = "1548-5595",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Protocol Biopsies

T2 - Utility and Limitations

AU - Huang, Yihung

AU - Farkash, Evan

PY - 2016/9/1

Y1 - 2016/9/1

N2 - As both T cell and antibody–mediated rejection can have a subclinical phase, protocol biopsies provide an early opportunity to intervene before the onset of clinical allograft dysfunction. Protocol biopsies are usually done after reperfusion to establish baseline, between 3 and 6 months to identify subclinical rejection, and at 6-12 months to assess chronicity and persistent inflammation that have prognostic implication. Treatment of both subclinical T cell and antibody–mediated rejection prevents progression of rejection and development of interstitial fibrosis/tubular atrophy or transplant glomerulopathy. Although subclinical rejection has become less frequent in low-risk patients on triple immunosuppression containing tacrolimus, protocol biopsies may still be useful in selected population. Protocol biopsies are more likely to benefit patients at higher risk for rejection, including those who are highly sensitized, transplanted across donor-specific antibody barriers, or on calcineurin inhibitor/corticosteroids sparing regimens. Interstitial fibrosis on protocol biopsies, especially in conjunction with persistent inflammation, predicts lower allograft survival.

AB - As both T cell and antibody–mediated rejection can have a subclinical phase, protocol biopsies provide an early opportunity to intervene before the onset of clinical allograft dysfunction. Protocol biopsies are usually done after reperfusion to establish baseline, between 3 and 6 months to identify subclinical rejection, and at 6-12 months to assess chronicity and persistent inflammation that have prognostic implication. Treatment of both subclinical T cell and antibody–mediated rejection prevents progression of rejection and development of interstitial fibrosis/tubular atrophy or transplant glomerulopathy. Although subclinical rejection has become less frequent in low-risk patients on triple immunosuppression containing tacrolimus, protocol biopsies may still be useful in selected population. Protocol biopsies are more likely to benefit patients at higher risk for rejection, including those who are highly sensitized, transplanted across donor-specific antibody barriers, or on calcineurin inhibitor/corticosteroids sparing regimens. Interstitial fibrosis on protocol biopsies, especially in conjunction with persistent inflammation, predicts lower allograft survival.

KW - Allograft survival

KW - Protocol biopsies

KW - Subclinical rejection

UR - http://www.scopus.com/inward/record.url?scp=84994177758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994177758&partnerID=8YFLogxK

U2 - 10.1053/j.ackd.2016.09.002

DO - 10.1053/j.ackd.2016.09.002

M3 - Review article

VL - 23

SP - 326

EP - 331

JO - Advances in Chronic Kidney Disease

JF - Advances in Chronic Kidney Disease

SN - 1548-5595

IS - 5

ER -